Genmab (DB:GE91) - Stock Price, News & Analysis

GE91 Stock Overview

Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

GE91 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 81.7% below our estimate of its fair value

Earnings are forecast to grow 19.98% per year

Earnings grew by 19.4% over the past year

Risk Analysis

No risks detected for GE91 from our risk checks.

Genmab A/S Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€930.5m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.6b

2invest

XTRA:2INV

€60.4m

Price History & Performance

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Price	DKK 21.00
52 Week High	DKK 33.80
52 Week Low	DKK 21.00
Beta	0.86
11 Month Change	-13.93%
3 Month Change	-11.76%
1 Year Change	-37.87%
33 Year Change	-42.31%
5 Year Change	n/a
Change since IPO	-23.62%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GE91	DE Biotechs	DE Market
7D	-8.7%	-0.7%	1.0%
1Y	-37.9%	-17.7%	11.2%

Return vs Industry: GE91 underperformed the German Biotechs industry which returned -17.7% over the past year.

Return vs Market: GE91 underperformed the German Market which returned 11.2% over the past year.

Price Volatility

Is GE91's price volatile compared to industry and market?
GE91 volatility
GE91 Average Weekly Movement	4.2%
Biotechs Industry Average Movement	6.0%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: GE91 has not had significant price volatility in the past 3 months.

Volatility Over Time: GE91's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	2,526	Jan G.J. de Winkel	www.genmab.com

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.

Genmab A/S Fundamentals Summary

How do Genmab's earnings and revenue compare to its market cap?
GE91 fundamental statistics
Market cap	€13.61b
Earnings (TTM)	€743.09m
Revenue (TTM)	€2.55b

18.3x

P/E Ratio

5.3x

P/S Ratio

Is GE91 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GE91 income statement (TTM)
Revenue	DKK 19.02b
Cost of Revenue	DKK 580.00m
Gross Profit	DKK 18.44b
Other Expenses	DKK 12.90b
Earnings	DKK 5.54b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	87.24
Gross Margin	96.95%
Net Profit Margin	29.13%
Debt/Equity Ratio	0%

How did GE91 perform over the long term?

See historical performance and comparison